Newsfilter article unlocker

Enter Newsfilter article ID in the field below.
Example: https://newsfilter.io/articles/39be1bef03e66cdc886c08a2a6319c47

Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; Alector cuts 49% of staff.